CTSO Cytosorbents Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1175151 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.3%
TTM net income YoY-70.4%
TTM EPS YoY-205.0%
Revenue 3-yr CAGR0.3%
Net income 3-yr CAGR—
Margins
Gross margin72.9%
Operating margin-30.0%
Net margin-46.7%
FCF margin-18.7%
EBITDA margin-26.8%
Returns
ROE-521.5%
ROA-42.2%
ROIC (approx.)-39.8%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets106.2%
Debt / equity—
Current ratio0.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.39x
Accruals ratio-25.7%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.73M | $9.63M | $8.86M | $9.23M | $9.48M | $9.62M | $8.73M | $9.15M |
| Cost of revenue | $2.40M | $2.58M | $2.73M | $2.43M | $2.82M | $2.80M | $2.52M | $2.90M |
| Gross profit | $7.33M | $7.05M | $6.13M | $6.80M | $6.67M | $6.81M | $6.21M | $6.25M |
| R&D expense | $1.15M | $1.45M | $1.02M | — | $918,000 | $1.26M | $1.66M | — |
| SG&A expense | $7.10M | $7.96M | $8.15M | $9.44M | $8.61M | $9.17M | $8.43M | $7.63M |
| Operating income | -$1.17M | -$2.64M | -$3.04M | -$4.38M | -$2.86M | -$3.62M | -$3.89M | -$3.40M |
| Pretax income | -$2.05M | — | — | -$5.50M | -$3.57M | — | -$1.48M | -$9.26M |
| Income tax | $0 | $0 | $0 | $0 | -$401,000 | $0 | $0 | -$1.69M |
| Net income | -$2.05M | -$4.57M | -$5.38M | -$5.50M | -$3.17M | $1.95M | -$1.48M | -$7.57M |
| EBITDA | -$869,000 | -$2.34M | -$2.75M | -$4.09M | -$1.96M | -$3.31M | -$3.58M | -$3.24M |
| EPS (basic) | -0.65 | -1.46 | -1.72 | — | -1.01 | 0.03 | -0.02 | — |
| EPS (diluted) | -0.65 | -1.46 | -1.72 | — | -1.01 | 0.03 | -0.02 | — |
| Weighted avg. shares (diluted) | 3.15M | 62.81M | 62.74M | — | 3.14M | 67.17M | 60.73M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.21M | $4.41M | $4.81M | $6.25M | $7.54M | $10.20M | $13.11M | $9.76M |
| Receivables | $7.07M | $6.79M | $7.15M | $7.55M | $7.43M | $7.74M | $7.67M | $7.32M |
| Inventory | $3.23M | $3.69M | $4.48M | $5.28M | $4.00M | $3.71M | $3.02M | $2.73M |
| Current assets | $15.44M | $15.74M | $17.76M | $20.63M | $21.31M | $22.99M | $25.41M | $21.60M |
| PP&E, net | $6.89M | $7.17M | $7.51M | $7.82M | $8.19M | $8.47M | $8.72M | $9.00M |
| Intangibles | $2.80M | $2.86M | $2.95M | $3.23M | $3.59M | $3.74M | $3.70M | $3.72M |
| Total assets | $37.16M | $37.96M | $40.56M | $44.18M | $45.75M | $47.99M | $50.78M | $47.37M |
| Current liabilities | $28.03M | $24.02M | $16.30M | $9.71M | $10.11M | $9.84M | $9.74M | $9.82M |
| Short-term debt | $17.52M | $14.15M | $6.65M | — | — | — | — | — |
| Long-term debt | $17.52M | $3.09M | $10.31M | $16.67M | $14.57M | $14.38M | $14.19M | $14.00M |
| Total debt | $35.05M | $17.24M | $16.96M | $16.67M | $14.57M | $14.38M | $14.19M | $14.00M |
| Total liabilities | $39.47M | $38.71M | $38.37M | $38.28M | $36.73M | $36.40M | $36.24M | $36.27M |
| Shareholders' equity | -$2.31M | -$751,000 | $2.19M | $5.90M | $9.02M | $11.59M | $14.54M | $11.11M |
| Net debt | $30.84M | $12.83M | $12.15M | $10.42M | $7.03M | $4.17M | $1.08M | $4.23M |
| Shares outstanding | 3.15M | 62.84M | 62.73M | 3.14M | 62.79M | 62.61M | 62.53M | 54.83M |
| Cash flow statement | ||||||||
| Operating cash flow | -$267,000 | -$583,000 | -$1.16M | -$4.83M | -$2.58M | -$1.51M | -$3.47M | -$2.34M |
| Capital expenditure | $20,000 | $14,000 | $11,000 | $108,000 | $17,000 | $36,879 | $2,000 | $69,343 |
| Free cash flow | -$287,000 | -$597,000 | -$1.17M | -$4.93M | -$2.59M | -$1.55M | -$3.47M | -$2.41M |
| Investing cash flow | -$4,000 | $7,000 | -$46,000 | -$291,000 | $55,000 | -$131,758 | -$47,000 | -$124,000 |
| Financing cash flow | — | — | — | $2.48M | $0 | -$1,134 | $6.83M | $167,000 |
| Depreciation & amortization | $300,000 | $300,000 | $289,000 | $295,000 | $900,000 | $300,000 | $306,000 | $154,000 |
| Stock-based compensation | $291,000 | $368,000 | $544,000 | $886,000 | $488,000 | $571,000 | $818,000 | $920,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.